Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy.

Nikolaou M, Karakantza M, Adonakis G, Theodorou G, Zoumbos N, Decavalas G.

Med Pregl. 2012 Sep-Oct;65(9-10):436-9.

PMID:
23214340
2.

High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.

Liga M, Triantafyllou E, Tiniakou M, Lambropoulou P, Karakantza M, Zoumbos NC, Spyridonidis A.

Biol Blood Marrow Transplant. 2013 Jan;19(1):75-81. doi: 10.1016/j.bbmt.2012.07.021. Epub 2012 Aug 4.

PMID:
22871557
3.

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.

Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators.

Lancet Oncol. 2011 Aug;12(8):773-84. doi: 10.1016/S1470-2045(11)70150-4. Epub 2011 Jul 1.

PMID:
21724462
4.

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.

Porter JB, Lin KH, Beris P, Forni GL, Taher A, Habr D, Domokos G, Roubert B, Thein SL; EPIC study investigators.

Eur J Haematol. 2011 Oct;87(4):338-48. doi: 10.1111/j.1600-0609.2011.01660.x. Epub 2011 Jul 29.

5.

Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia.

Spyridonidis A, Liga M, Triantafyllou E, Themeli M, Marangos M, Karakantza M, Zoumbos N.

Bone Marrow Transplant. 2011 Oct;46(10):1363-8. doi: 10.1038/bmt.2010.308. Epub 2010 Dec 20.

6.

Successful mobilization with plerixafor and autologous hematopoietic SCT in a patient with refractory Hodgkin's lymphoma and Gaucher disease.

Symeonidis A, Liga M, Triantafyllou E, Kouraklis A, Tiniakou M, Karakantza M, Spyridonidis A, Zoumbos N.

Bone Marrow Transplant. 2011 Aug;46(8):1161-2. doi: 10.1038/bmt.2010.263. Epub 2010 Nov 8. No abstract available.

PMID:
21057554
7.

Horizontal DNA transfer from donor to host cells as an alternative mechanism of epithelial chimerism after allogeneic hematopoietic cell transplantation.

Waterhouse M, Themeli M, Bertz H, Zoumbos N, Finke J, Spyridonidis A.

Biol Blood Marrow Transplant. 2011 Mar;17(3):319-29. doi: 10.1016/j.bbmt.2010.09.001. Epub 2010 Sep 15.

PMID:
20837151
8.

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.

Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D, Domokos G, Roubert B, Porter JB; EPIC study investigators.

Blood. 2010 Oct 7;116(14):2448-54. doi: 10.1182/blood-2010-01-261289. Epub 2010 Jun 21.

9.

Human herpesvirus 6-related pure red cell aplasia, secondary graft failure, and clinical severe immune suppression after allogeneic hematopoietic cell transplantation successfully treated with foscarnet.

Lagadinou ED, Marangos M, Liga M, Panos G, Tzouvara E, Dimitroulia E, Tiniakou M, Tsakris A, Zoumbos N, Spyridonidis A.

Transpl Infect Dis. 2010 Oct;12(5):437-40. doi: 10.1111/j.1399-3062.2010.00515.x.

PMID:
20561301
10.

Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission.

Gorin NC, Labopin M, Reiffers J, Milpied N, Blaise D, Witz F, de Witte T, Meloni G, Attal M, Bernal T, Rocha V; Acute Leukemia Working Party, European Cooperative Group for Blood and Marrow Transplantation.

Blood. 2010 Oct 28;116(17):3157-62. doi: 10.1182/blood-2009-11-252197. Epub 2010 May 17.

11.

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.

Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C; EPIC study investigators.

Leuk Res. 2010 Sep;34(9):1143-50. doi: 10.1016/j.leukres.2010.03.009. Epub 2010 May 6.

PMID:
20451251
12.

Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro study and implications to secondary neoplasia.

Themeli M, Petrikkos L, Waterhouse M, Bertz H, Lagadinou E, Zoumbos N, Finke J, Spyridonidis A.

Leukemia. 2010 Mar;24(3):536-43. doi: 10.1038/leu.2009.284. Epub 2010 Jan 14.

PMID:
20072151
13.

Cardiac mortality in {beta}-thalassemia major: resting but not dobutamine stress echocardiography predicts mortality among initially cardiac disease-free patients in a prospective 12-year study.

Hahalis G, Kourakli A, Gerasimidou I, Kalogeropoulos AP, Sitafidis G, Papageorgiou U, Davlouros P, Grapsas N, Zoumbos NC, Alexopoulos D.

Eur J Heart Fail. 2009 Dec;11(12):1178-81. doi: 10.1093/eurjhf/hfp152. Epub 2009 Nov 4.

PMID:
19889689
14.

Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alpha.

Tsopra OA, Ziros PG, Lagadinou ED, Symeonidis A, Kouraklis-Symeonidis A, Thanopoulou E, Angelopoulou MK, Vassilakopoulos TP, Pangalis GA, Zoumbos NC.

Acta Haematol. 2009;121(4):187-95. doi: 10.1159/000220331. Epub 2009 May 26.

PMID:
19468203
15.

Lung function measurements in traditional bakers.

Patouchas D, Efremidis G, Karkoulias K, Zoumbos N, Goumas P, Spiropoulos K.

Acta Biomed. 2008 Dec;79(3):197-203.

PMID:
19260379
16.

The functional role of S/MARs in episomal vectors as defined by the stress-induced destabilization profile of the vector sequences.

Giannakopoulos A, Stavrou EF, Zarkadis I, Zoumbos N, Thrasher AJ, Athanassiadou A.

J Mol Biol. 2009 Apr 17;387(5):1239-49. doi: 10.1016/j.jmb.2009.02.043. Epub 2009 Feb 25.

PMID:
19248788
17.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group.

Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.

18.

Consensus statement on iron overload in myelodysplastic syndromes.

Bennett JM; MDS Foundation's Working Group on Transfusional Iron Overload.

Am J Hematol. 2008 Nov;83(11):858-61. doi: 10.1002/ajh.21269.

PMID:
18767130
19.

Inherited thrombophilia screening in Greek women with recurrent fetal loss.

Mougiou A, Androutsopoulos G, Karakantza M, Theodori E, Decavalas G, Zoumbos N.

Clin Exp Obstet Gynecol. 2008;35(3):172-4.

PMID:
18754285
20.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators.

N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk